Eculizumab in secondary atypical haemolytic uraemic syndrome.

ABSTRACT:

Background

Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.

Methods

We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 × 10 9 /L) and haemoglobin, disappearance of all the markers of microangiopathic haemolytic anaemia (MAHA), and improvement of renal function, with a ≥25% reduction of serum creatinine from the onset of eculizumab administration.

Results

Twenty-nine patients with secondary aHUS (15 drug-induced, 8 associated with system

SUBMITTER: Cavero T 

PROVIDER: S-EPMC5410989 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature